| Researchers terminate trial examining aliskiren in high-risk patients - Endocrine Today |
|
|
Endocrine Today Novartis recently announced its decision to halt a trial assessing the safety and efficacy of aliskiren for treatment of hypertension in patients with type 2 diabetes and renal impairment who are at high risk for cardiovascular and renal events, |